2025-09-15 - Analysis Report
Okay, here's an analysis of Merck & Co. (MRK) based on the information you provided. I'll present the information in English, with simple numbers first, followed by a concise analysis.

## Merck & Co. (MRK) Stock Analysis

**0. Overview:**

*   **Ticker:** MRK
*   **Company:** Merck & Co Inc
*   **Description:** A global pharmaceutical company focused on developing and marketing innovative medicines and vaccines.

**1. Performance vs. S&P 500 (VOO):**

*   **MRK Cumulative Return:** -9.69%
*   **VOO Cumulative Return:** 104.48%
*   **Absolute Divergence:** -98.3%
*   **Relative Divergence:** 0.0 (This means MRK's performance is at the very bottom of its historical range compared to VOO over the period examined).

**Analysis:** MRK has significantly underperformed the S&P 500. The relative divergence suggests this underperformance is at the extreme end of its historical trend.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD      | Alpha   | Beta  | Cap(B) |
| ---------- | ------- | -------- | ------- | ----- | ------ |
| 2015-2017  | 5.0%    | 58.2%    | -24.0%  | -0.0  | 134.1  |
| 2016-2018  | 43.0%   | 66.4%    | 25.0%   | -0.1  | 182.1  |
| 2017-2019  | 40.0%   | 66.4%    | 11.0%   | 0.3   | 216.8  |
| 2018-2020  | 20.0%   | 66.4%    | 0.0%    | 0.3   | 195.0  |
| 2019-2021  | -1.0%   | 65.6%    | -50.0%  | 0.3   | 191.4  |
| 2020-2022  | 13.0%   | 69.5%    | 11.0%   | 0.3   | 277.1  |
| 2021-2023  | 31.0%   | 69.5%    | 13.0%   | 0.3   | 272.3  |
| 2022-2024  | -7.0%   | 69.5%    | -33.0%  | 0.2   | 248.5  |
| 2023-2025  | -62.0%  | 71.5%    | -118.0% | 0.5   | 206.8  |

**Analysis:**

*   **CAGR:** The Compounded Average Growth Rate has fluctuated significantly, with recent periods showing negative growth.
*   **MDD:** The Maximum Drawdown is consistently high, indicating substantial risk.
*   **Alpha:** Alpha is generally negative, particularly in recent years, showing underperformance relative to the benchmark.
*   **Beta:** Beta values are generally low, suggesting that the stock is less sensitive to market movements.
*   **Cap:** Market capitalization has varied, reflecting overall market conditions and company performance.

**2. Recent Stock Price Movement:**

*   **Current Price:** 82.81
*   **Previous Close:** 85.15
*   **Change:** -2.75
*   **5-Day Moving Average:** 84.138
*   **20-Day Moving Average:** 84.5723
*   **60-Day Moving Average:** 82.3524

**Analysis:** The stock price is currently below both the 5-day and 20-day moving averages, indicating a short-term downward trend. It is slightly above the 60-day moving average. The recent price drop suggests negative momentum.

**3. Technical Indicators & Expected Return:**

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 31.04 (Approaching oversold territory)
*   **PPO:** -0.254
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **20-Day Relative Divergence Change:** -2.1 (Negative - indicates short-term decline)
*   **Expected Return:** 70.3% (Long-term, relative to S&P 500)

**Analysis:** The RSI suggests the stock may be approaching oversold conditions. The negative change in relative divergence confirms short-term downward momentum. The Hybrid Signal is cautioning to buy the stock at the 80% of cash, indicating low cash ratio(0%). Despite recent weakness, the MRI indicates low risk, and the expected return is quite high, suggesting potential for long-term outperformance. The significant price drop from the previous close (-2.75) indicates some recent negative news or market reaction.

**4. Recent News & Significant Events:**

*   **Positive:**
    *   Leerink Partners Remains Bullish on Merck & Co. (MRK)
    *   Merck & Co., Inc. (MRK) Reports Positive Topline Results from its Phase 3 CORALreef Lipids Trial
*   **Neutral/General:**
    *   2 Healthcare Dividend Stocks to Buy and Hold
    *   Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
    *   Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
*   **Potentially Negative (Indirect):**
    *   Exclusive-AstraZeneca pauses $270 million investment in Britain

**Analysis:** The news is mixed. Positive trial results and analyst support are counterbalanced by general healthcare sector news. AstraZeneca's investment pause in Britain could signal broader economic concerns.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.96 (~Buy)
*   **Target Price:** Average 102.33 (Considerably higher than the current price)

**Analysis:** Analyst sentiment is generally positive, with a "Buy" consensus and a target price significantly above the current level, suggesting potential upside.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
| ---------- | ---- | --------- |
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2024-08-05 | 2.15 | 16.11 B$  |
| 2025-08-05 | 2.15 | 16.11 B$  |

**Analysis:**  Earnings per share (EPS) and revenue have fluctuated. There is a downtrend in EPS in the latest quarter (1.76) compared to previous quarters (2.01, 2.15). Revenues are relatively stable but show some variability.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| ------------ | ---------- | ------------- |
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |
| 2024-06-30   | $16.11B   | 76.76%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
| ------------ | ---------- | --------- |
| 2025-06-30   | $48.99B   | 9.04%     |
| 2025-03-31   | $48.34B   | 10.51%    |
| 2024-12-31   | $46.31B   | 8.08%     |
| 2024-09-30   | $44.50B   | 7.09%     |
| 2024-06-30   | $43.58B   | 12.52%    |

**Analysis:** Revenue and profit margins are generally strong. Equity is increasing, but Return on Equity (ROE) has been volatile, with a recent decline.

**7. Overall Summary:**

MRK has significantly underperformed the S&P 500 recently. Technical indicators suggest it may be approaching oversold conditions. Recent earnings show a decline in EPS. However, analyst sentiment is positive, with a "Buy" consensus and a considerably higher target price. The Market Risk Indicator suggests low risk, and the expected long-term return is high. The recent price drop and negative short-term momentum should be considered. The positive news regarding trial results provides some reassurance.

**In conclusion:** MRK presents a mixed picture. While there are short-term concerns and underperformance relative to the market, analysts are optimistic, and long-term growth potential remains. A potential investment would require careful consideration of the risks and potential rewards.
